Drug profile · INN
etranacogene dezaparvovec
HEMGENIX
etranacogene dezaparvovec (HEMGENIX) is a coagulation factor ix exogenous protein.
EMA: approved Blood and blood forming organs (B02) B02BD
Patents linked 0
Pipeline programs 0
News articles 1
Drug details — etranacogene dezaparvovec
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
etranacogene dezaparvovec (HEMGENIX) is a coagulation factor ix exogenous protein.
Key facts
INN etranacogene dezaparvovec
Brand HEMGENIX
Mechanism Coagulation factor IX exogenous protein
Target Coagulation factor IX
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD
Mechanism of action
Coagulation factor IX exogenous protein
Primary target: Coagulation factor IX
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is etranacogene dezaparvovec?
etranacogene dezaparvovec (HEMGENIX) is a coagulation factor ix exogenous protein.
What is the brand name for etranacogene dezaparvovec?
HEMGENIX is a marketed brand name for etranacogene dezaparvovec. Check FDA Drugs@FDA for the current US label holder and prescribing information.